New government drug repurposing programs: Opportunities and uncertainties.
Johnathon LiddicoatAshleigh HamidzadehKathleen LiddellMarco SchitoDavid SimonMateo AboyTimo MinssenPublished in: Science translational medicine (2024)
Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, partially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europe have created seven drug development programs that aim to overcome these challenges using a variety of different strategies.